Abivax SA has raised €28 million from US and European investors to advance development of its lead small molecule drug, ABX464, in several inflammatory indications and Covid-19. ABX464 recently reported positive data in a Phase 2a study of patients with ulcerative colitis including a high remission rate at the end of a second year of treatment.
A readout of Phase 2b data in this indication is expected in the second quarter of 2021. ABX464 is also being studied in Crohn’s disease, rheumatoid arthritis, and as an antiviral treatment for HIV.